Lumrotatug Biosimilar - Research Grade

Human

CD38

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human CD38 (OKT10) Antibody (ICH1157), Daratumumab Biosimilar - Research Grade (ICH4020), Isatuximab Biosimilar - Research Grade (ICH5028), Erzotabart Biosimilar - Research Grade (ICH5533), Felzartamab Biosimilar - Research Grade (ICH5547), Mezagitamab Biosimilar - Research Grade (ICH5679)

https://www.imgt.org/mAb-DB/

ICH3002

P28907

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of Lumrotatug (also known as CM-313), an anti-CD38 human IgG1-kappa monoclonal antibody, supplied for research use only. It is built around the same human CD38 target as the originator drug and is intended as a laboratory reagent, not the clinical drug, and not for human or veterinary use. Because it reproduces the binding specificity and IgG1-kappa framework of the reference molecule, it is useful as a well-defined positive control and reference standard in CD38 assays, for benchmarking other anti-CD38 candidates, and for characterizing CD38-expressing cell lines and primary cells. Manufactured recombinantly in an unconjugated format, it supports downstream labeling, ADC or bispecific development workflows, and epitope or binning studies. Research-grade material is offered low-endotoxin (<1 EU/mg, with an ultra-low <0.5 EU/mg option) and in bulk milligram-to-gram quantities, making it suitable for in-vitro assay development, cell-based neutralization or effector-function work, and preclinical model studies where a consistent, high-purity anti-CD38 analog is required at scale. CD38 (UniProt P28907) is a type II single-pass transmembrane glycoprotein that functions both as a receptor and as a multifunctional ectoenzyme. Its extracellular domain catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and NAADP from NAD+ and NADP+, generating second messengers that regulate intracellular calcium signaling. CD38 is broadly expressed on hematopoietic cells, including plasma cells, activated T and B cells, NK cells, and myeloid cells, and is a marker of lymphocyte activation. It is strongly and uniformly overexpressed on malignant plasma cells, which underlies its role as a therapeutic target in multiple myeloma. Through its enzymatic activity CD38 also contributes to NAD+ metabolism and, in the tumor microenvironment, to immunosuppressive adenosine generation. Antibodies against CD38 can mediate target-cell killing via ADCC, ADCP, and complement-dependent cytotoxicity, and can modulate CD38 enzymatic function.

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, ADPRC 1, cADPr hydrolase 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Lumrotatug biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Lumrotatug biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lumrotatug biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lumrotatug that binds CD38; for research use only.